Severe Respiratory Syncytial Virus Pneumonia Complicating Fludarabine and Cyclophosphamide Treatment of Chronic Lymphocytic Leukemia

Eur J Haematol. 2002 Jul;69(1):54-7. doi: 10.1034/j.1600-0609.2002.02745.x.

Abstract

The potential for life-threatening pneumonia due to respiratory syncytial virus (RSV) infection is recognised among patients with acute leukaemia and recipients of allogeneic or autologous bone marrow transplantation. RSV pneumonia has a high mortality rate in these settings. Less intensively treated patients are not usually considered to be at risk for serious RSV pneumonia. We describe the case of a 62-yr-old patient with chronic lymphocytic leukaemia (CLL) treated with fludarabine and cyclophosphamide who developed severe RSV pneumonia and recovered following treatment including intravenous ribavirin.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Cyclophosphamide / adverse effects*
  • Cyclophosphamide / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / etiology*
  • Ribavirin / therapeutic use
  • Vidarabine / adverse effects*
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Antineoplastic Agents
  • Antiviral Agents
  • Immunosuppressive Agents
  • Ribavirin
  • Cyclophosphamide
  • Vidarabine
  • fludarabine